Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Nicaragua: These 5 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Nicaragua: These 5 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can XALKORI (crizotinib) generic drug versions launch in Nicaragua?

Generic name: crizotinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2027
Generic Entry Controlled by: Nicaragua Patent 200,700,057
Patent Title: COMPUESTOS DE AMINOHETEROARILO ENANTIOMÉRICAMENTE PUROS COMO INHIBIDORES DE PROTEINA QUINASA

XALKORI is a drug marketed by Pf Prism Cv. There are three patents protecting this drug.

See drug price trends for XALKORI.

The generic ingredient in XALKORI is crizotinib. Additional details are available on the crizotinib profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Nicaragua?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Nicaragua Patent 200,900,203

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Nicaragua?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Nicaragua Patent 200,900,207
Patent Title: UNA COMPOSICIÓN DE LIBERACIÓN PROLONGADA QUE COMPRENDE UN DERIVADO DE SOMATOSTATINA EN MICROPARTÍCULAS.

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Nicaragua?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Nicaragua Patent 200,900,216

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Nicaragua?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Nicaragua Patent 201,000,105
Patent Title: RÉGIMEN DE DOSIFICACIÓN ASOCIADO CON ÉSTERES DE PALIPERIDONA INYECTABLES DE ACCIÓN PROLONGADA.

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

Nicaragua Branded and Generic Drug Market Assessment, Regulation, Patent Risk and Commercial Opportunities

Last updated: October 11, 2026

Nicaragua’s pharmaceutical market is import-dependent, price-sensitive and split between public procurement, private retail and social-security purchasing. Generic medicines have the strongest volume opportunity, while branded products retain advantages in physician preference, hospital supply, chronic-care adherence and originator confidence. Regulatory access is feasible but requires local execution, Spanish-language documentation, sanitary registration, import authorization and reliable pharmacovigilance.

The main commercial opportunities are essential medicines, chronic disease therapies, hospital products, biosimilars and quality-assured branded generics. The principal risks are public-sector payment and tender concentration, foreign-exchange exposure, registration delays, weak demand forecasting, informal distribution and limited transparency around market data.

What is the structure of Nicaragua’s pharmaceutical market?

Nicaragua has three principal pharmaceutical channels:

Channel Main buyers Commercial characteristics
Public health system Ministry of Health, public hospitals and government procurement entities Tender-driven, price-sensitive and concentrated among essential medicines
Private retail Pharmacies, distributors, physicians and patients More receptive to branded generics, originator brands and chronic therapies
Social security Instituto Nicaragüense de Seguridad Social and affiliated providers Prescribing and reimbursement depend on institutional formularies and supplier contracts

The Ministry of Health, or MINSA, is the central public-health authority. Public procurement is highly important because Nicaragua has a large publicly financed health-care component and relatively low average household purchasing power. The private channel is more commercially flexible but remains sensitive to price, availability and physician recommendation.

Nicaragua does not publish a single, comprehensive, regularly updated market figure covering retail sales, public procurement, social-security purchases and hospital consumption. Market evaluations therefore generally rely on customs data, distributor information, tender records, pharmacy audits and company-level sales data.

Which drug categories have the strongest demand?

Demand is structurally strongest in:

  • Anti-infectives and medicines for respiratory disease
  • Cardiovascular products, including antihypertensives
  • Diabetes therapies
  • Analgesics and anti-inflammatory medicines
  • Gastrointestinal medicines
  • Women’s health products
  • Pediatric formulations
  • Hospital injectables and anti-infectives
  • Oncology and specialty medicines supplied through institutional channels

Nicaragua’s epidemiological profile supports continued demand for chronic disease medicines while infectious disease, maternal health and pediatric products remain important in public procurement. The private market is more likely to support differentiated brands, combination products, adherence-focused packaging and products with physician-driven demand.

How large is Nicaragua’s branded and generic drug market?

Generics are expected to account for most unit demand because of government procurement practices, affordability constraints and the role of essential-medicine programs. Branded products generally command higher prices but compete against local, regional and multinational generic manufacturers.

The market is best divided into four commercial segments:

  1. Originator brands with patent or regulatory differentiation.
  2. Branded generics marketed under proprietary names.
  3. Unbranded or international nonproprietary-name generics.
  4. Hospital and specialty products purchased through tenders or institutional contracts.

Branded generics often occupy the middle ground between low-cost commodity products and multinational originators. They can obtain a price premium when supported by reliable supply, physician promotion, quality documentation and distributor coverage.

How does Nicaragua compare with other Central American markets?

Nicaragua is smaller than Guatemala, Costa Rica, Panama and El Salvador in market depth and private-sector purchasing power. It is more price-sensitive and more dependent on public and institutional procurement. Costa Rica and Panama offer higher-value private and specialty opportunities, while Guatemala has a larger commercial market. Nicaragua can be attractive for regional distributors seeking Central American coverage, but it generally does not justify a high fixed-cost standalone infrastructure for every product category.

A regional strategy commonly uses a Central American regulatory and distribution platform, with local representation and country-specific registration maintained in Nicaragua.

What is Nicaragua’s drug regulatory framework?

The principal legal framework includes Nicaragua’s Medicines and Pharmacies Law, Law No. 292, and its implementing regulations. MINSA administers pharmaceutical regulation through the competent pharmacy and medicines authorities. The framework covers registration, importation, manufacturing, distribution, dispensing, quality control and pharmacovigilance (Republic of Nicaragua, 1998).

A company placing a medicine on the Nicaraguan market normally must address:

  • Legal representation in Nicaragua
  • Manufacturer authorization and good manufacturing practice evidence
  • Product registration
  • Technical and pharmaceutical documentation
  • Certificate of pharmaceutical product or equivalent regulatory certificate
  • Certificate of free sale where applicable
  • Stability data
  • Labeling and package inserts in Spanish
  • Import permits and customs documentation
  • Batch and quality-control information
  • Pharmacovigilance responsibilities

The regulatory file must be aligned with the product category. Prescription medicines, over-the-counter products, biologics, vaccines, controlled substances and medical products can face different documentation and operational requirements.

What is the FDA regulatory status of medicines sold in Nicaragua?

FDA approval is not a substitute for Nicaraguan registration. A U.S. approval, European authorization or approval from another reference agency can strengthen the technical file, but the product still requires local authorization before commercial sale in Nicaragua.

A foreign certificate may support reliance or abridged review where accepted by the Nicaraguan authority, but reliance does not eliminate local legal-representative, labeling, importation and post-market obligations.

How are generic medicines registered in Nicaragua?

Generic registration generally depends on proof of pharmaceutical quality, safety and efficacy. Depending on the product and applicable rules, authorities may require evidence of therapeutic equivalence or bioequivalence, especially for products with narrow therapeutic margins, modified release, complex delivery systems or high clinical risk.

The key commercial distinction is between:

  • A conventional immediate-release generic with a well-established active ingredient
  • A branded generic requiring a stronger commercial positioning file
  • A complex generic requiring clinical, bioequivalence, device or manufacturing data
  • A biological product requiring a more specialized comparability package

A company entering through a generic product should assume that the registration file, manufacturing-site documentation, stability package and Spanish labeling will determine timing more than patent barriers.

What patents protect medicines in Nicaragua?

Nicaragua applies patent protection under its domestic industrial-property framework and international obligations, including the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights. The normal patent term is generally 20 years from the filing date, subject to applicable national rules and adjustments.

Nicaragua does not operate a U.S.-style FDA Orange Book system. There is no single public Orange Book equivalent that systematically links approved products to listed patents and generic certifications. A competitor therefore must conduct a separate freedom-to-operate review covering:

  • Composition-of-matter patents
  • Salt, polymorph and stereoisomer claims
  • Formulation and dosage-form patents
  • Use and dosing patents
  • Manufacturing-process patents
  • Device and delivery-system rights
  • Patent ownership and assignments
  • National-phase filings and expiration dates

What is the regulatory data-exclusivity risk?

Under the CAFTA-DR intellectual-property framework, protection may apply to undisclosed test data and other information submitted for marketing approval of certain pharmaceutical products. The relevant analysis depends on whether the product qualifies as a new chemical entity, the date of first marketing approval and the relationship between the protected data and the later applicant’s submission (United States Trade Representative, 2004).

Regulatory data protection and patent protection are separate. A product may have no enforceable patent in Nicaragua but still face a regulatory barrier if protected clinical or test data cannot be relied upon by a generic applicant. Conversely, data protection may have expired while formulation, process or use patents remain relevant.

When does a branded medicine lose exclusivity in Nicaragua?

Loss of exclusivity depends on four separate dates:

Exclusivity component Key timing question
Compound patent When does the national patent expire?
Secondary patent Are formulation, dosage, use or process claims still in force?
Regulatory data protection Has the applicable data-protection period ended?
Regulatory registration Can a generic obtain its own sanitary authorization?

Nicaragua’s patent system does not create a reliable universal launch date from the brand’s global expiry date. The relevant date is the expiry of enforceable Nicaraguan rights, combined with any data-protection period and the time required for local registration.

Patent extensions, supplementary protection mechanisms or pediatric extensions should not be assumed without confirming the applicable Nicaraguan legal basis. A U.S. patent term adjustment or European supplementary protection certificate does not automatically apply in Nicaragua.

What patent litigation and Paragraph IV risks exist?

Nicaragua does not use the U.S. Hatch-Waxman Paragraph IV certification system. A generic applicant does not normally file a U.S.-style Paragraph IV notice to trigger automatic patent litigation or a statutory 30-month stay.

The practical risk is different:

  • Patent infringement proceedings may be initiated under national law.
  • Customs and border measures may affect imported goods.
  • Injunction risk depends on the asserted right and procedural posture.
  • Regulatory approval and patent enforcement are not necessarily integrated.
  • A local distributor may face commercial pressure even without a formal suit.

A generic launch plan should therefore use a country-specific freedom-to-operate opinion rather than rely on U.S. ANDA certifications, Orange Book status or U.S. settlement precedent.

What biosimilar opportunities exist in Nicaragua?

Biosimilars offer opportunity in oncology, immunology, endocrinology and supportive care, but the market presents higher regulatory and commercial complexity than small-molecule generics.

A biosimilar strategy requires review of:

  • Local rules for biological-product registration
  • Reference-product selection
  • Comparability and analytical characterization
  • Immunogenicity evidence
  • Pharmacovigilance and traceability
  • Interchangeability or substitution rules
  • Hospital tender specifications
  • Cold-chain reliability
  • Originator patent and regulatory-data status

Nicaragua’s public procurement system can create access opportunities for lower-cost biologics, but tender qualification, supply continuity and clinical confidence can outweigh nominal price. Biosimilar entrants should expect a hospital-led commercialization model rather than a conventional retail-pharmacy launch.

Which companies are positioned in Nicaragua’s drug market?

The market includes multinational originators, Central American manufacturers, Mexican and Colombian pharmaceutical companies, local importers, regional distributors and domestic generic marketers. Competitive strength depends less on global size than on:

  • Existing MINSA and hospital tender eligibility
  • Registration portfolio
  • Distributor relationships
  • Inventory and cold-chain capability
  • Ability to finance working capital
  • Spanish-language medical promotion
  • Pharmacovigilance systems
  • Tender-compliance experience

A company without a local commercial organization will usually need a licensed distributor or local representative. The right partner can reduce entry time, but the arrangement should allocate responsibility for registration ownership, product release, recalls, adverse-event reporting, inventory losses and public-tender performance.

What licensing deals and entry structures work best?

The main entry structures are:

Structure Best use Primary risk
Local distributor Fastest route for established products Margin loss and limited control over demand
Exclusive license Brands needing local promotion and registration ownership Dependence on partner performance
Regional distributor Portfolio expansion across Central America Nicaragua may receive lower priority
Local contract manufacturing Products with sustained volume or tender demand Quality-system and capital requirements
Direct subsidiary Large portfolio and long-term institutional strategy Higher fixed costs and compliance burden

License agreements should expressly address ownership of the Nicaraguan registration, renewal obligations, regulatory variations, product recalls, minimum purchases, pharmacovigilance, anti-corruption controls and post-termination inventory.

What are the main regulatory and commercial challenges?

The most significant challenges are:

  1. Public procurement concentration and tender-price pressure.
  2. Limited transparency in total market-size data.
  3. Dependence on imports and exposure to logistics disruptions.
  4. Registration and variation-management workload.
  5. Need for Spanish-language technical and promotional materials.
  6. Working-capital requirements for distributors and public accounts.
  7. Potentially uneven enforcement against counterfeit or substandard products.
  8. Limited commercial attractiveness for low-volume specialty products.
  9. Patent and regulatory-data analysis conducted outside an Orange Book model.
  10. Cold-chain and pharmacovigilance requirements for biologics and vaccines.

Manufacturing is rarely the first barrier for conventional generics because many products can be imported from approved foreign facilities. The principal manufacturing risks involve GMP documentation, batch-release consistency, stability under local distribution conditions and continuity of supply. Local manufacturing becomes more relevant where public tenders reward domestic supply, where freight costs erode margins or where a regional plant can serve several countries.

What generic launch scenarios are most likely?

Immediate-release oral generic

This is the lowest-complexity opportunity. The launch depends primarily on registration readiness, price, distributor coverage and tender qualification. Patent risk may be limited where the active ingredient is long established, but secondary patents and data protection still require review.

Branded chronic-care generic

This model can support higher margins than a commodity generic. Success depends on physician promotion, adherence, consistent availability and pharmacy relationships. Cardiovascular, diabetes and gastrointestinal therapies are commercially relevant categories.

Complex formulation

Modified-release, inhaled, transdermal and long-acting products face higher technical and equivalence barriers. Their value proposition is stronger, but the registration file and manufacturing controls are more demanding.

Biosimilar

The opportunity is concentrated in institutional and hospital purchasing. The launch requires a credible scientific package, pharmacovigilance capacity and reliable cold-chain execution.

How strong is Nicaragua’s pharmaceutical patent estate?

Patent strength is product-specific rather than market-wide. Nicaragua is unlikely to be the highest-risk jurisdiction in a regional launch because market size limits the economic value of litigation for some products. Risk rises when:

  • The product has an active composition patent.
  • The originator has multiple secondary patents.
  • A local injunction can interrupt imports.
  • The product is high value and concentrated in a small number of hospitals.
  • The generic depends on the originator’s protected regulatory data.
  • The importer has weak contractual protection against enforcement action.

A written patent landscape should identify Nicaraguan national-phase patents, ownership changes, annuity status, expiration dates and claim scope. Global patent expiry data is not sufficient.

What is the commercial outlook for Nicaragua?

Nicaragua is most attractive for companies with a focused, regional portfolio and an experienced local partner. The strongest opportunities are quality-assured generics, branded generics, essential medicines, hospital injectables, chronic-care products and selected biosimilars.

The weakest opportunities are low-volume products requiring extensive promotion, products with fragile cold-chain economics, and highly commoditized medicines where public tenders reduce margins below sustainable distribution costs.

Revenue exposure should be modeled by channel rather than by total national market. A portfolio heavily dependent on government tenders will have different payment, margin and concentration risks from a private-retail portfolio. Companies should also model currency, inventory days, tender renewal cycles, registration fees, distributor rebates and product-return obligations.

Key Takeaways

  • Nicaragua is a price-sensitive, import-dependent pharmaceutical market.
  • Generics and branded generics are positioned for the broadest volume opportunity.
  • Public procurement and institutional sales have disproportionate commercial importance.
  • MINSA registration, local representation, Spanish labeling and import compliance are central entry requirements.
  • Nicaragua has no U.S.-style Orange Book or Paragraph IV pathway.
  • Patent, regulatory-data and formulation risks must be reviewed separately.
  • Biosimilars have potential but require stronger regulatory, clinical and supply-chain capabilities.
  • The best entry model is usually a qualified local or regional distributor with explicit regulatory and pharmacovigilance obligations.
  • Commercial success depends on tender access, continuity of supply, pricing discipline and local execution more than on brand recognition alone.

FAQs on Nicaragua’s pharmaceutical market

Does Nicaragua recognize FDA approval for generic medicines?

FDA approval can support the technical file, but it does not replace Nicaraguan sanitary registration, local representation, Spanish labeling or import authorization.

Can a generic medicine launch in Nicaragua before a U.S. patent expires?

Potentially, but the analysis must focus on enforceable Nicaraguan patents, regulatory-data protection and local infringement risk. U.S. patent expiry is not determinative.

Are medicines in Nicaragua required to have Spanish labeling?

Medicines marketed in Nicaragua generally require labeling and package information appropriate for the local regulatory market, including Spanish-language information and required product details.

Is pharmaceutical advertising to physicians permitted in Nicaragua?

Promotion is subject to applicable medicines, advertising and professional rules. Prescription-product promotion should be controlled through approved labeling, compliant medical information and documented promotional practices.

Is local pharmaceutical manufacturing required to sell medicines in Nicaragua?

No general local-manufacturing requirement applies to all medicines. Imported products can enter through compliant manufacturers, local representatives, registration holders and importers, subject to applicable regulatory requirements.

References

  1. Republic of Nicaragua. (1998). Ley No. 292, Ley de medicamentos y farmacias. La Gaceta, Diario Oficial.

  2. World Health Organization. (2014). WHO medicines regulatory assessment tool: Global benchmarking tool for evaluation of national regulatory systems of medicines. World Health Organization.

  3. World Health Organization. (2019). WHO guideline on country pharmaceutical pricing policies. World Health Organization.

  4. Pan American Health Organization. (2022). Health in the Americas+: Nicaragua. PAHO.

  5. United States Trade Representative. (2004). Dominican Republic-Central America-United States Free Trade Agreement. Office of the United States Trade Representative.

  6. World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights. WTO.

  7. International Trade Administration. (2023). Nicaragua country commercial guide: Healthcare and pharmaceuticals. U.S. Department of Commerce.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.